Lunai Bioworks Inc. (LNAI) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Lunai Bioworks Inc. (LNAI) closed at USD 0.89 on 2026-10-14, a change of -89.3 % over the past year, with a market capitalization of USD 3.74M.

Lunai Bioworks Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Lunai Bioworks Inc. key figures

Previous close

USD 0.89 (2026-10-14)

1-year change

-89.3 %

Market cap

USD 3.74M

Enterprise value

USD 3.93M

P/E ratio (trailing)

-0.02

P/E ratio (forward)

n/a

EPS (trailing)

-49.12

EPS (forward)

n/a

PEG ratio

n/a

Price to book

-0.42

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

3.26

Employees

12

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Lunai Bioworks Inc.

Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States, Canada, and the Netherlands. It operates through two segments, RENB and BioSymetrics. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer. It also develops BioSymetrics platform, for multi-omics integration for target identification and validation; clinical trial optimization, including patient stratification and response monitoring; and screening of gene and small molecule effects for the purpose of identifying novel drug targets and therapeutics. The company was formerly known as Renovaro Inc. and changed its name to Lunai Bioworks Inc. in August 2025. Lunai Bioworks Inc. is based in Sacramento, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Lunai Bioworks Inc. and compare it with other stocks.